drugset / Trial / NCT00785356
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
RandomizedParallel-groupDouble-blindTreatment
Summary
Subjects will be randomly assigned to one of 3 treatment groups and receive 325 mg (65 mg elemental iron) iron supplements twice daily.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telapristone Acetate | Other / unclassified | 25 mg | — |
| Subject | Telapristone Acetate | Other / unclassified | 50 mg | — |